# Century Therapeutics (IPSC) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/IPSC
## Company Profile
- Ticker: IPSC
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology
## Stock Data
- Close: 2.06 USD
- Market cap: 391369935.53 USD
- Last updated: 2026-08-11
## Business Overview
### iPSC Cell Therapy Company
Century Therapeutics develops induced pluripotent stem cell-derived therapies for autoimmune disease, type 1 diabetes, and cancer.
### CNTY-813
CNTY-813 is an iPSC-derived islet-cell replacement therapy designed to restore insulin production while using Allo-Evasion engineering to reduce immune rejection.
### CNTY-308
CNTY-308 is a CD19-directed CAR-iT cell therapy intended for autoimmune diseases and manufactured as a scalable off-the-shelf product.
## Why The Stock Is Moving

As of Aug 11, 2026, IPSC closed up 4.04% at $2.06. No new same-company headline was identified in the current news window.

## Future Catalysts

- An IND submission for CNTY-813 is planned for the fourth quarter of 2026.
- Initial CNTY-813 clinical data are expected in the second half of 2027.
- Century plans to advance CNTY-308 into clinical development during 2026.

## Recent News
- 2026-07-09 12:00 EST — [Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026](https://biopharmsignal.com/news/IPSC/century-therapeutics-selected-for-oral-presentations-of-cnty-813-preclinical-dat-b81a8a73) — Source: Century Therapeutics
- 2026-06-08 20:05 EST — [New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026](https://biopharmsignal.com/news/IPSC/new-cnty-813-preclinical-data-demonstrate-durable-glucose-control-immune-evasion-e65eb4fc) — Source: Century Therapeutics
- 2026-05-13 12:00 EST — [Century Therapeutics Reports First Quarter Financial Results and Business Updates](https://biopharmsignal.com/news/IPSC/century-therapeutics-reports-first-quarter-financial-results-and-business-update-c4d76676) — Source: Century Therapeutics
- 2026-04-30 20:05 EST — [Century Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions](https://biopharmsignal.com/news/IPSC/century-therapeutics-selected-for-oral-presentation-of-cnty-813-preclinical-data-0932a2d5) — Source: Century Therapeutics
- 2026-03-12 12:00 EST — [Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates](https://biopharmsignal.com/news/IPSC/century-therapeutics-reports-full-year-2025-financial-results-and-business-updat-7b62a847) — Source: Century Therapeutics